]>
IRCT20090117001556N138 IRCT 2021-08-03 Tehran University of Medical Sciences Famotidine for the improvement of cognitive impairments in COVID-19 patients Investigating the effect of Famotidine on cognitive and behavioral dysfunctions induced by COVID-19: A randomized double blind and placebo controlled clinical trial 2021-09-23 anticipated 50 Complete https://irct.ir/trial/57828 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Permuted block randomization: using blocks with n=4; AABB, ABAB, ABBA, BABA, BAAB, BBAA. We randomly use the blocks to achieve total sample size. ("A" and "B" are the study groups), Blinding description: The participants, care providers and outcome assessors will be blind regarding grouping. All the participants believe that they are taking the main medication (the participants who are taking placebo are not aware of it). Care providers and outcome assessors do not know which participants have received the main medication and which participants have received placebo. Thus, there is no orientation in their work process. 2-3 COVID-19. Intervention 1: Intervention group: Famotidine 80 mg per day for 3 months. Intervention 2: Control group: Placebo for 3 months. Yes - There is a plan to make this available What will be shared: The data will be distributed through final report When: 5 years from 2021 to 2026 To whom: academic researchers Conditions: users should cite the resource of data Where to obtain: Prof Shahin Akhondzadeh How to obtain: by E mail Comments:
public Shahin Akhondzadeh
Roozbeh Hospital, South Kargar Street, Tehran
Tehran Iran (Islamic Republic of) 1333715914 +98 21 5541 2222 s.akhond@sina.tums.ac.ir Tehran University of Medical Sciences scientific Prof. Shahin Akhondzadeh
Roozbeh Hospital, South Kargar Street, Tehran
Tehran Iran (Islamic Republic of) 1333715914 +98 21 5541 2222 s.akhond@sina.tums.ac.ir Tehran University of Medical Sciences Iran (Islamic Republic of) History of hospitalization due to COVID-19 At least 20 days from the onset of symptoms, and 7 days from the last day of symptoms passed Diagnosis of cognitive impairment (score 23 or less in MMSE test, or score 22 or less in MoCA test) Age between 18-65 18 years 65 years Both Being psychotic Presence of other psychiatric disorders Using other psychiatric drugs or any drug which can affect cognitive performance History of ECT during past 2 months Presence of thyroid disease Presence of kidney disease Presence of liver disease History of cognitive impairment or dementia Pregnant or lactating women U07.1 COVID-19, virus identified Treatment - Drugs Placebo Intervention group: Famotidine 80 mg per day for 3 months. Control group: Placebo for 3 months Severity of cognitive impairment. Timepoint: Baseline and months 1.5 and 3. Method of measurement: by Mini mental state Exam (MMSE), Montreal Cognitive Assessment (MoCA), Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A). Tehran University of Medical Sciences Approved 2021-02-27 Ethics Committee of Tehran University of Medical Sciences Tehran University of Medical Sciences, Qhods St., Keshavarz Blvd. Tehran Tehran Iran (Islamic Republic of)